SOLVD Health

News Release

SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

SAN DIEGO (BUSINESSWIRE) — December 17, 2025 — SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript™ has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated laboratory markets in the nation.

Pharmacogenomic testing plays a critical role in precision medicine, helping clinicians tailor drug therapies based on an individual’s genetic profile. By identifying genetic variations that influence drug metabolism and response, PGx testing empowers providers to optimize treatment plans, reduce adverse drug reactions, and improve patient outcomes.

“Approval from the New York State Department of Health underscores our commitment to delivering actionable insights that transform healthcare,” said Dr. Keri Donaldson, Founder and President of SOLVD Health. “Pharmacogenomics is a cornerstone of personalized medicine, and this clearance allows us to expand access to tools that help clinicians make safer, more effective prescribing decisions.”

This achievement builds on SOLVD Health’s proven track record of innovation, including its FDA-approved AvertD® test, the first genetic test designed to assess elevated risk for opioid use disorder prior to prescribing oral opioids. Leveraging AI-powered analytics and proprietary algorithms, SOLVD Health continues to advance its mission of preventing disease and improving health outcomes through predictive, personalized insights.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

Media Contact:
Katie Kennedy
Gregory
solvd@gregoryfca.com

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

December 15, 2025 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility.

read more
SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

December 9, 2025 – SOLVD Health is launching two studies to validate our GLP‑1 patient stratification platform, bringing precision medicine to obesity and type 2 diabetes care. “As the worldwide prevalence of obesity and type 2 diabetes continues to grow, the need for more targeted, personalized treatment methods becomes increasingly critical,” Dr. Keri Donaldson, Founder and President, SOLVD Health.

read more
SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

May 12, 2025 – SOLVD Health appoints diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.

read more